Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors-Reference-Cited by-同舟云学术

Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors

Published:2022-08-27 Issue:11 Volume:11 Page:1294-1307
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Sharma Shringi¹,Pepin Xavier²,Burri Harini¹,Zheng Lianqing¹,Kuptsova‐Clarkson Nataliya³,de Jong Anouk⁴,Yu Ting¹,MacArthur Holly L.⁵,Majewski Michal⁵,Byrd John C.⁶,Furman Richard R.⁷,Ware Joseph A.¹,Mann James⁸,Ramies David¹,Munugalavadla Veerendra¹,Sheridan Louise⁹,Tomkinson Helen¹⁰

Affiliation:

1. AstraZeneca South San Francisco California USA

2. New Modalities and Parenteral Development Pharmaceutical Technology & Development Operations AstraZeneca Macclesfield, England UK

3. AstraZeneca Gaithersburg Maryland USA

4. Acerta Pharma B.V. Oss The Netherlands

5. AstraZeneca Mississauga Ontario Canada

6. Department of Internal Medicine and University of Cincinnati Cancer Center University of Cincinnati College of Medicine Cincinnati Ohio USA

7. New York‐Presbyterian/Weill Cornell Medicine New York New York USA

8. Oral Product Development Pharmaceutical Technology & Development Operations AstraZeneca Macclesfield, England UK

9. Pharmaceutical Technology & Development Operations AstraZeneca Macclesfield, England UK

10. AstraZeneca Cambridge, England UK

Publisher